Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪185.84 M‬USD
−3.99USD
‪−58.98 M‬USD
‪15.97 M‬
Beta (1Y)
−1.79

About Outlook Therapeutics, Inc.

CEO
C. Russell Trenary
Headquarters
Iselin
Employees (FY)
24
Founded
2010
ISIN
US69012T3059
FIGI
BBG00469JRJ5
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of OTLK is 8.29 USD — it has decreased by 3.72% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Outlook Therapeutics, Inc. stocks are traded under the ticker OTLK.
Outlook Therapeutics, Inc. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
OTLK stock is 8.79% volatile and has beta coefficient of −1.79. Check out the list of the most volatile stocks — is Outlook Therapeutics, Inc. there?
One year price forecast for Outlook Therapeutics, Inc. has a max estimate of 60.00 USD and a min estimate of 25.00 USD.
OTLK earnings for the last quarter are −1.00 USD per share, whereas the estimation was −1.15 USD resulting in a 13.04% surprise. The estimated earnings for the next quarter are −0.99 USD per share. See more details about Outlook Therapeutics, Inc. earnings.
Outlook Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪2.49 M‬ USD.
Yes, you can track Outlook Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
OTLK stock has fallen by 8.80% compared to the previous week, the month change is a 9.22% rise, over the last year Outlook Therapeutics, Inc. has showed a 62.32% decrease.
OTLK net income for the last quarter is ‪−11.18 M‬ USD, while the quarter before that showed ‪−12.99 M‬ USD of net income which accounts for 13.95% change. Track more Outlook Therapeutics, Inc. financial stats to get the full picture.
Today Outlook Therapeutics, Inc. has the market capitalization of ‪178.93 M‬, it has decreased by 3.61% over the last week.
No, OTLK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, OTLK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Outlook Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
OTLK reached its all-time high on Sep 1, 2016 with the price of 878.40 USD, and its all-time low was 4.00 USD and was reached on Sep 8, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 24.00 employees. See our rating of the largest employees — is Outlook Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Outlook Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Outlook Therapeutics, Inc. stock shows the sell signal. See more of Outlook Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Outlook Therapeutics, Inc. future price: according to them, OTLK price has a max estimate of 60.00 USD and a min estimate of 25.00 USD. Read a more detailed Outlook Therapeutics, Inc. forecast: see what analysts think of Outlook Therapeutics, Inc. and suggest that you do with its stocks.